The IKBKB Knockout 143B Polyclonal Cells comprise a polyclonal population of 143B human osteosarcoma cells engineered via CRISPR/Cas9 to disrupt the IKBKB gene, which encodes the IKK-?? kinase. This polyclonal knockout format provides a heterogeneous pool of cells with IKBKB gene disruption, enabling loss-of-function analysis at the population level without single-cell cloning. It is suitable for experiments where pooled cellular responses to pathway perturbations are of interest, such as signaling studies and drug screens.
The 143B cell line is a widely used model of human osteosarcoma, derived from a bone tumor and characterized by aggressive growth and metastatic potential. This host background is highly relevant for cancer research, particularly for studying the molecular mechanisms underlying bone tumor biology, including pathways that drive proliferation, survival, and treatment resistance. The 143B line is a well-established platform for evaluating novel therapeutic targets in osteosarcoma.
IKBKB encodes the serine/threonine kinase IKK-??, a core component of the IKK complex, which includes IKK-?? (IKBKA) and NEMO (IKBKG). Upon stimulation by TNF??, IL-1??, or LPS, adaptors such as TRAF6 and the kinase TAK1 activate the IKK complex, leading to IKK-??-mediated phosphorylation of I??B??. This promotes I??B?? ubiquitination and proteasomal degradation, releasing NF-??B (p65/p50) for nuclear translocation. Nuclear NF-??B drives transcription of target genes including IL-6, IL-8, TNF??, BCL2, BCL-XL, cyclin D1, and c-Myc. IKBKB disruption blocks I??B?? phosphorylation, stabilizing cytoplasmic NF-??B and impairing expression of these downstream effectors.
In osteosarcoma, aberrant NF-??B signaling contributes to tumor progression, chemoresistance, and immune modulation. The IKBKB knockout in 143B cells specifically inactivates IKK-??, providing a precise tool to dissect its role in these pathological processes. This model allows investigation of how loss of IKK-?? affects canonical NF-??B activity and crosstalk with other pathways such as MAPK signaling, which is often co-opted in cancer. By eliminating key NF-??B-mediated transcriptional programs, the polyclonal knockout cells enable analysis of IKK-??-dependent phenotypes, including altered cytokine secretion, apoptosis resistance, and proliferative capacity in a bone cancer microenvironment.
This polyclonal knockout resource is designed for a variety of downstream assays. Western blotting can be used to verify decreased phospho-I??B?? levels and total I??B?? stabilization. NF-??B luciferase reporter assays quantify transcriptional activity, while RT-qPCR can profile changes in target gene expression (e.g., IL6, TNF). Immunofluorescence microscopy enables visualization of p65 cytoplasmic retention, and ELISA assays measure cytokine secretion changes. Functional studies can assess apoptosis via caspase-3/7 activity and cell proliferation using MTS or BrdU assays. The model is also suitable for screening IKK-?? inhibitors or evaluating drug sensitivity in an osteosarcoma context. For technical support or custom inquiries, please contact Ascent Research.
